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SUMMARY

The teratogenic potential of Zika virus (ZIKV) has
made the development of an effective vaccine a
global health priority. Here, we generate two gorilla
adenovirus-based ZIKV vaccines that encode for
pre-membrane (prM) and envelope (E) proteins
(GAd-Zvp) or prM and the ectodomain of E protein
(GAd-Eecto). Both vaccines induce humoral and
cell-mediated immune responses and prevent
lethality after ZIKV challenge in mice. Protection is
antibody dependent, CD8+ T cell independent, and
for GAd-Eecto requires the complement component
C1q. Immunization of GAd-Zvp induces antibodies
against a key neutralizing epitope on domain III of E
protein and confers durable protection as evidenced
by memory B and long-lived plasma cell responses
and challenge studies 9 months later. In two models
of ZIKV infection during pregnancy, GAd-Zvp prevents maternal-to-fetal transmission. The gorilla
adenovirus-based vaccine platform encoding fulllength prM and E genes is a promising candidate
for preventing congenital ZIKV syndrome and
possibly infection by other flaviviruses.
INTRODUCTION
Zika virus (ZIKV) was isolated in Uganda in 1947 (Dick, 1952) and
for decades remained restricted to African and Asian countries
where sporadic human infections were reported (Jan et al.,
1978; Olson et al., 1981). However, during the past decade,
large-scale ZIKV epidemics have occurred in the Yap Islands,
French Polynesia, and the Americas (Cao-Lormeau et al.,
2014; Duffy et al., 2009; Roth et al., 2014). African and Asian lineages of ZIKV exist and comprise a single serotype (Dowd et al.,
2016a). ZIKV isolates of the Asian lineage are responsible for

recent epidemics in Oceania and the Americas (Berthet et al.,
2014; Enfissi et al., 2016).
While infections historically cause a mild, self-limiting febrile
illness accompanied by arthralgia, myalgia, rash, and headache
(Zanluca et al., 2015), since its emergence in the Western hemisphere in 2015, ZIKV has become a global public health problem
because infections during pregnancy caused microcephaly,
developmental anomalies, or miscarriage of fetuses (van der
Eijk et al., 2016; Mlakar et al., 2016; Pierson and Diamond,
2018). ZIKV infection in adults also is linked to the development
of Guillain-Barré syndrome (GBS), a debilitating autoimmune
disorder that affects peripheral nervous system function (Brasil
et al., 2016; Cao-Lormeau et al., 2016; Oehler et al., 2014).
Although ZIKV is spread principally by Aedes aegypti mosquitos
(Boorman and Porterfield, 1956), other transmission routes have
been described. Sexual transmission of ZIKV, with the ability to
persist in vaginal secretions and semen for months, has been
documented (Foy et al., 2011; Musso et al., 2015), and vertical
transmission from infected mothers to fetuses causes congenital
Zika syndrome (CZS) (Besnard et al., 2014; Mlakar et al., 2016).
ZIKV is an enveloped virus, with an 11-kilobase positive-sense
RNA that is translated into a polyprotein composed of three
structural (capsid [C], pre-membrane [prM], and envelope [E])
and seven non-structural (NS1, NS2A, NS2B, NS3, NS4A, 2K,
NS4B, and NS5) proteins (Kuno and Chang, 2007). ZIKV virions
form in the lumen of the endoplasmic reticulum as an immature
virion composed of 60 prM-E heterotrimers (Prasad et al.,
2017). The expression of prM is required for the biogenesis of
ZIKV virions or virus-like particles (VLPs) (Roby et al., 2015);
secreted VLPs are encoded by the full-length prM and E genes
and can form during infection or when expressed in isolation (Allison et al., 1995). In the acidic environment of the Golgi network,
a furin-mediated protease cleavage of prM occurs, and the pr
peptide is released in the extracellular space, which results in
the generation of a mature, infectious virion or VLP. The ectodomain of the ZIKV E protein is composed of three domains (DI, DII
and DIII) and the target of most neutralizing antibodies and vaccines (Diamond et al., 2019; Richner and Diamond, 2018).
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Because of its impact on global public health, substantial
effort has been made toward developing vaccines against
ZIKV, although none yet have been approved and only some
have advanced to clinical testing in humans. Several vaccine
platforms have been evaluated including DNA plasmids (Dowd
et al., 2016b; Larocca et al., 2016), inactivated virions (Abbink
et al., 2016; Larocca et al., 2016), modified mRNA (Pardi et al.,
2017; Richner et al., 2017a), VLPs (Boigard et al., 2017), and viral
€rnberger
vectors (Abbink et al., 2017; Emanuel et al., 2018; Nu
et al., 2019). Adenovirus-vectored vaccines, including human
adenovirus (hAd5)-based vectors, represent a promising platform for multiple pathogens, as they offer excellent safety profiles and scalability for industrial production and induce robust
and balanced immune responses (Wold and Toth, 2013). Nevertheless, two major limitations are associated with their use: (1)
pre-existing immune responses to hAd5 can blunt immunity to
the transgene, as hAd5 seroprevalence reaches to 35%–50%
in human populations (Barouch et al., 2011; Nwanegbo et al.,
2004; Xiang et al., 2006); and (2) while Ad5 and chimpanzee
adenovirus type 3 (ChAd3) induce robust immune responses
against encoded transgenes, other adenoviruses have been
less immunogenic (Abbink et al., 2007; Colloca et al., 2012; Geisbert et al., 2011; Stanley et al., 2014).
Adenovirus-based vaccines against ZIKV have been evaluated. A rhesus monkey adenovirus (RhAd52) encoding for the
M and E (but lacking the pr component) proteins induced protective immunity against ZIKV in mice and non-human primates
(NHP) (Abbink et al., 2016; Larocca et al., 2016). A chimpanzee
adenovirus (ChAd7) encoding for the M and E proteins protected
mice against testicular damage (Xu et al., 2018), and a human
adenovirus type 26 (Ad26) expressing ZIKV M and E proteins
protected in mice and NHP (Cox et al., 2018). Incorporation of
the full prM gene with E in human adenovirus type 2 (hAd2) backbone enhanced immunogenicity compared to hAd2 expressing
only ZIKV E (Liu et al., 2018). Despite these promising results,
none of the adenovirus-based vaccines against ZIKV have

been tested in animal models to prevent in utero transmission
during pregnancy. However, passive protection was observed
in challenged pups (at day 7 post-birth) of dams immunized
with an hAd5 expressing ZIKV E fused to the T4 fibritin foldon trimerization domain (Kim et al., 2016).
Gorilla adenoviruses (GAd) have potential as a vectored vaccine platform (Johnson et al., 2014; Limbach et al., 2017) since
less than 6% of US population shows seropositivity (Johnson
et al., 2014). Indeed, a GAd-based vaccine against malaria
was more effective than an Ad5-vectored vaccine (Limbach
et al., 2017). Here, we describe the development of GAd that
encode for the full-length prM and E proteins (GAd-Zvp) or prM
and a truncated E protein (GAd-Eecto) of an Asian genotype
ZIKV strain. Although both vaccines were immunogenic and
conferred protection in a lethal challenge model of ZIKV infection, GAd-Zvp induced substantially higher levels of neutralizing
antibodies. A single dose of GAd-Zvp induced durable B and
T cell immunity and prevented maternal-to-fetal transmission
of ZIKV in both immunocompromised and immunocompetent
mice.
RESULTS
GAd-Eecto and GAd-Zvp Induce Anti-ZIKV Antibody
Responses
We constructed three E1-deleted, replication defective GAds:
GAd-control, GAd-Eecto, and GAd-Zvp containing no transgene, prM-E ectodomain of Asian strain H/PF/2013 (amino acids
123–696, sequence ID AHZ13508.1), and full-length prM-E
(amino acids 123–794), respectively, with the target genes inserted under the transcriptional control of a cytomegalovirus
(CMV) promoter in place of the deleted E1 gene (Figure 1A).
The prM-E ectodomain construct results into a soluble form of
E protein alone, whereas the prM-E full-length protein assembles
into a VLP (Garg et al., 2017; Yang et al., 2017). The production
of ZIKV VLPs in the supernatants of A549 cells infected with

Figure 1. Immunogenicity of GAd-ZIKV Vaccines in WT C57BL/6 Mice
(A) Schematic representation of the transgene cassettes. GAd-control has no transgene insert, whereas GAd-Eecto and GAd-Zvp contain ZIKV
(strain H/PF/2013) a full prM-E cassette or prM-E ectodomain, respectively.
(B) A549 cells were infected with GAd-Eecto or GAd-Zvp followed by concentration of the supernatants by ultracentrifugation, negative staining, and transmission
electron microscopy imaging to confirm the production of VLPs. High-power images are shown and compared to ZIKV VLP preparation generated by transfection
of prM-E genes. Scale bar, 100 nm.
(C) ZIKV E protein expression in GAd-Eecto or GAd-Zvp. A549 cells were infected with GAd-Eecto, GAd-Zvp, or mock-infected, and supernatants were prepared
and run on SDS-PAGE under reducing (upper blot) or non-reducing (lower blot) conditions along with recombinant ZIKV E ectodomain protein followed by
detection using ZV-48. One representative blot from three experiments is shown.
(D–H) C57BL/6 mice were immunized with 109 viral particles of GAd-control, GAd-Eecto, or GAd-Zvp via intramuscular inoculation and boosted 3 weeks later.
(D and E) Humoral responses were evaluated in the sera of immunized mice at day 21 post-prime and day 21 post-boost. An ELISA measured ZIKV E-specific
binding IgG (D), and a FRNT determined neutralization activity (EC50 values are shown) (E). Data for humoral responses are pooled from two experiments with
n = 10–18 per group (ANOVA with a Dunnett’s post-test comparing vaccine and control groups: ****p < 0.0001).
(F) Localization of GAd-Zvp and GAd-Eecto-induced polyclonal antibodies from sera. Binding to ZIKV Eecto, DIII, or DIII-LR mutant (A310E and T335K) was
determined by ELISA from sera obtained post-boost at day 42 (n = 17 per group, ANOVA with a Tukey’s post-test: ns, not significant; *p < 0.05; **p < 0.01;
****p < 0.0001).
(G–J) Cell-mediated immune responses were analyzed at 90–110 days post-initial immunization. Splenocytes were assayed for IFN-g+ ZIKV E-specific CD8+
T cells using intracellular staining after peptide restimulation. Representative flow cytometry plots of four experiments are shown with percentages of IFN-g+
ZIKV-specific CD8+ T cells (G). Summary of frequencies of IFN-g+ ZIKV-specific CD8+ T cells are shown (H). ZIKV E-specific MBCs per million CD19+ cells
obtained from the spleen were determined by ELISA and Poisson distribution analysis (see STAR Methods) (I). An ELISPOT determined the number of ZIKVspecific IgG producing LLPCs per million bone marrow cells (J). Bars indicate median values per vaccine group. Data for cell mediated responses are pooled from
four experiments with n = 6–17 animal per group (ANOVA with a Dunnett’s post-test comparing vaccine and control groups: ns, not significant; **p < 0.01;
***p < 0.001). In this figure, dotted lines represent the limit of detection (LOD) of the assays.
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GAd-Zvp but not GAd-Eecto was confirmed by electron microscopy (Figure 1B). Furthermore, E protein expression was
confirmed in the supernatants of GAd-Zvp- or GAd-Eecto-infected A549 cells by western blotting with an anti-ZIKV E protein
monoclonal antibody (mAb ZV-48; Zhao et al., 2016; Figure 1C).
To evaluate the immunogenicity of GAd-Eecto and GAd-Zvp in
immunocompetent mice, 8-week-old C57BL/6 mice were vaccinated by intramuscular inoculation with 109 virus particles of
GAd-Eecto, GAd-Zvp, or GAd-control. Three weeks later, mice
were boosted with a second dose of the same vaccine. Serum
samples were collected at 3 weeks post-primary immunization
and at 3 weeks post-booster immunization. An ELISA with
ZIKV E protein was used to determine virus-specific immunoglobulin G (IgG) responses. Both GAd-Eecto and GAd-Zvp
induced high levels of ZIKV E-specific IgG compared to the control vector (Figure 1D), with reciprocal mean endpoint titers of
171,732 ± 87,886 and 42,842 ± 21,977 after a single immunization, respectively. The ZIKV E-specific IgG titers were boosted
slightly with the second dose of GAd-Eecto and GAd-Zvp
(mean titers of 189,414 ± 126,876 and 118,826 ± 73,022, respectively). To assess the levels of neutralizing antibodies, focusreduction neutralization tests (FRNT) were performed. Whereas
a single dose of either vaccine induced neutralizing antibody
against ZIKV (Figure 1E), the levels were higher for GAd-Zvp
(mean effective half maximal inhibitory concentration [EC50] of
396 ± 126) than GAd-Eecto (EC50 of 71 ± 78.5). Although a
booster dose of GAd-Zvp augmented neutralization titers (EC50
of 1,796 ± 919), only a small increase was observed after the
GAd-Eecto boost (EC50 of 113 ± 94).
Neutralizing antibodies isolated from ZIKV-infected individuals
recognize epitopes on DI/II, DIII, E dimer epitopes, and quaternary epitopes formed by adjacent E proteins (Fernandez et al.,
2017; Robbiani et al., 2017; Sapparapu et al., 2016; Stettler
et al., 2016). DIII-specific mAbs have potently neutralizing activity against ZIKV (Robbiani et al., 2017; Sapparapu et al., 2016;
Stettler et al., 2016; Wang et al., 2017), and those binding to
the lateral ridge epitope (DIII-LR) efficiently protect mice against
ZIKV challenge (Zhao et al., 2016). We evaluated whether the
GAd-Eecto and GAd-Zvp vaccines differentially induced DIIILR-specific antibodies by performing parallel binding assays
with Eecto, DIII, or a DIII-LR mutant protein, the latter of which
encodes for loss-of-binding substitutions (A310E and T335K) in
the N-terminal region and BC loop of the epitope and abrogates
binding of several neutralizing mAbs (Zhao et al., 2016). Three
weeks after boosting (day 42), similar levels of polyclonal antibody against Eecto and DIII proteins were detected in sera
from the two vaccines (Figure 1F). Remarkably, polyclonal antibodies from GAd-Zvp- but not GAd-Eecto-vaccinated mice exhibited diminished binding to the DIII-LR mutant compared to
DIII protein. Thus, the antibody response of GAd-Zvp uniquely
was skewed toward the neutralizing DIII-LR epitope.
Vaccine-Induced Memory B and T Cell Responses
against ZIKV
To evaluate whether the GAd vaccines induced memory CD8+
T cell responses, mice were immunized and boosted as
described above, and splenocytes were harvested on days
90–110 after initial immunization. Splenic CD8+ T cells were

stained for intracellular expression of interferon (IFN)-g after
ex vivo restimulation with an H-2Db-restricted immunodominant
peptide (amino acids 294–302) in the ZIKV E protein (Elong
Ngono et al., 2017). IFN-g producing ZIKV E-specific CD8+
T cells were detected after immunization with GAd-Eecto
(3.0% ± 1.6) or GAd-Zvp (4.8% ± 2.3) but not with the GAd control vector (Figures 1G and 1H).
We also assessed the ability of the GAd vaccines to induce
ZIKV-specific memory responses in the B cell compartment.
CD19+ memory B cells (MBCs) from GAd-vaccinated and
boosted mice at days 90–110 after initial immunization were enriched from bulk splenocytes and then co-cultured for 6 days
with NIH 3T3 feeder cells ectopically expressing CD40L, BAFF,
and interleukin-21 (IL-21). Subsequently, supernatants from
MBCs were harvested, the levels of ZIKV E-specific IgG were
measured by ELISA, and the frequency of ZIKV E-specific
MBCs was determined by Poisson distribution (Purtha et al.,
2011). Both GAd-Zvp and GAd-Eecto induced ZIKV-specific
MBCs, although only the levels induced by GAd-Zvp attained
statistical significance compared to GAd-control vector (Figure 1I). Long-lived plasma cells (LLPCs), which principally reside
in the bone marrow, constitutively secrete high levels of antibody
and are the source of virus-specific IgG in circulation at times
remote from infection or vaccination (Manz et al., 1997). To evaluate the LLPC response after vaccination, CD138+ bone marrow
cells were harvested at days 90–110 and assayed for ZIKV
E-specific IgG production by ELISPOT. ZIKV E-specific LLPCs
were detected in the BM of GAd-Zvp-vaccinated mice but not
in GAd-Eecto or GAd-control-vaccinated mice (Figure 1J).
GAd-Eecto and GAd-Zvp Protect Mice against ZIKV
Lethal Challenge
C57BL/6 mice were immunized and boosted as described above
with GAd-Eecto, GAd-Zvp, or GAd-control vaccines. At day 45
post-initial immunization (24 days after boosting), animals were
challenged with 3 3 105 focus-forming units (FFUs) of a heterologous African strain of ZIKV strain (Dakar 41525) (Figure 2A),
which is more pathogenic in mice than the H/PF/2013 ZIKV strain
(Gorman et al., 2018; Lazear et al., 2016). One day prior to virus
inoculation, mice were treated with a single 2 mg dose of antiIfnar1 blocking antibody (MAR1-5A3) (Sheehan et al., 2006) to
facilitate a lethal ZIKV challenge model (Sapparapu et al.,
2016). Mice vaccinated with GAd-Eecto or GAd-Zvp were fully
protected against ZIKV-induced death, whereas those immunized with the control GAd vector had a 75% mortality rate (Figure 2B). At day 3 after ZIKV challenge, serum samples were
analyzed for viremia. At this time point, there was no detectable
viremia in any of the GAd-Zvp-vaccinated mice. In comparison,
the majority (6 of 9) mice immunized with GAd-Eecto had
measurable viremia (Figure 2C), although this was lower than in
mice given the GAd-control vaccine. To assess whether GAdZvp induced sterilizing immunity, antibody responses against
the non-structural protein NS1 were evaluated at day 9 after
ZIKV challenge, as a measure of ZIKV replication post-challenge.
Lower titers of anti-NS1 antibody titers were detected in GAdZvp mice compared to GAd-control or GAd-Eecto immunized
mice (Figure 2D). Thus, while GAd-Zvp protected against ZIKV
viremia and disease, it did not achieve sterilizing immunity.
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Figure 2. GAd-Eecto and GAd-Zvp Protect
Mice against Lethal ZIKV Challenge
Eight-week-old C57BL/6 female mice were
immunized with 109 viral particles of GAd-control
(n = 20), GAd-Eecto (n = 10), or GAd-Zvp (n = 10)
and boosted with a homologous dose 3 weeks
later. On day 45 post-initial immunization, mice
were challenged subcutaneously with 3 3 105
FFUs of ZIKV Dakar 41525 that was preceded by a
single 2 mg anti-Ifnar1 mAb treatment 1 day prior
to ZIKV infections.
(A) The experimental scheme of vaccination and
challenge.
(B) Mice were monitored for mortality for 21 days
following viral challenge (log-rank test with Bonferroni correction: ***p < 0.001).
(C) At day 3 after ZIKV challenge, serum was
collected and assayed for viral RNA using RTqPCR. The dotted line indicates the LOD of the
assay. Data are pooled from two experiments with
n = 9–20 mice per group (Kruskal-Wallis
ANOVA with Dunn’s post-test: ns, not significant;
***p < 0.001).
(D) An ELISA was used to measure serum antiNS1 antibody responses obtained at day 9 after
ZIKV challenge (n = 10 per group, ANOVA with a
Tukey’s post-test: ns, not significant; ***p < 0.001;
****p < 0.0001). In this figure, bars indicate median
values and dotted lines represent the limit of
detection (LOD) of the assays.

Mechanism of Vaccine Protection
To investigate the contribution of CD8+ T cell responses to vaccine-mediated protection, cell depletion studies were performed. C57BL/6 mice were immunized with GAd-Eecto,
GAd-Zvp, or GAd-control and boosted at day 21. At day 56
post-initial immunization, mice were challenged with 3 3 105
FFUs of ZIKV Dakar 41525 and monitored for survival. Mice
were treated with 500 mg of depleting anti-CD8 or isotype control antibody on days 7, 3, +1, +5, and +12. One day prior to
ZIKV challenge, mice also were inoculated with a single dose of
2 mg anti-Ifnar1 blocking antibody (MAR1-5A3). At day 7 postinfection, mice were bled and CD8+ T cell depletion was
confirmed in blood using flow cytometry (Figure 3A). Notably,
both CD8+ T cell-sufficient and depleted mice that were vaccinated with GAd-Eecto or GAd-Zvp survived lethal ZIKV challenge (Figure 3B), indicating a subordinate role for CD8+
T cells in GAd vaccine-induced protective immunity. In comparison, in the GAd-control-vaccinated group, CD8+ T celldepleted mice (18 out of 19) fared slightly worse than CD8+
T cell-sufficient mice (11 of 15) (Figure 3B), consistent with an
established role of CD8+ T cells in protection against primary
ZIKV infection in mice (Elong Ngono et al., 2017; Huang
et al., 2017; Winkler et al., 2017).
We performed passive transfer studies to define the contribution of antibody to vaccine-mediated protection. Sera
(100 mL) from GAd-Eecto, GAd-Zvp, or GAd-control-vaccinated
mice (obtained post-boost, at day 42) were transferred to naive
C57BL/6 mice at day 1, concurrent with inoculation of a single dose of anti-Ifnar1 blocking antibody (MAR1-5A3). At day 0,
mice were challenged with ZIKV Dakar 41525. Infected mice
that received serum from GAd-Zvp- or GAd-Eecto-immunized
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mice were completely protected against mortality (Figure 3C)
with no weight loss observed (Figure 3D). In comparison, and
as expected, mice receiving serum from GAd-control-treated
mice succumbed to ZIKV infection with substantial weight
loss and mortality. Thus, the humoral immune responses to
GAd-Eecto and GAd-Zvp is sufficient to protect against lethal
ZIKV challenge. Given the differences in neutralizing activity in
serum from GAd-Eecto and GAd-Zvp mice (see Figure 1D),
the equivalent levels of protection in the passive transfer experiments were unexpected. While this could reflect the relative
dosing of sera tested, we hypothesized that the complement
component C1q might augment the inhibitory activity of antibodies derived from GAd-Eecto immunization by reducing the
stoichiometric threshold for neutralization (Mehlhop et al.,
2009; Pierson et al., 2007). Indeed, in cell-culture experiments,
addition of soluble, purified C1q enhanced the neutralizing activity of serum from GAd-Eecto immunized mice (Figure 3E).
Based on these results, we repeated passive transfer experiments in C1q/ mice. Whereas C1q/ mice receiving serum
from GAd-Zvp-immunized animals remained protected (Figure 3F), those given serum from GAd-Eecto- or GAd-controlimmunized mice succumbed to ZIKV infection with a 100%
mortality rate. Thus, antibodies present in GAd-Eecto immune
sera required C1q and possibly other complement components
for protection in vivo.
GAd-Zvp Induces Durable Protective Immunity
For GAd-Zvp, our best vaccine candidate, we assessed the
durability and protective efficacy of humoral responses either
after priming only at day 0 or a two-dose priming and boost
(at day 21) regimen. FRNT assays were performed to evaluate

Figure 3. Mechanism of GAd-Eecto- and GAd-Zvp-Mediated Protection
(A and B) Effect of CD8+ T cell depletion on protection mediated by GAd-Eecto or GAd-Zvp. Six-week-old C57BL/6 mice were immunized with 1 3 10 9 vp of GAdEecto (n = 30), GAd-Zvp (n = 20), or GAd-control (n = 35). Three weeks later, a homologous dose of each vaccine was administered to each group of mice. Mice
were then treated with 500 mg of depleting anti-CD8 or isotype control antibody on days 7, 3, +1, +5, and +12. At day 0, mice were challenged subcutaneously
with 3 3 105 FFUs of ZIKV Dakar 41525 that was preceded by a single 2 mg anti-Ifnar1 mAb treatment 1 day prior to infection. At day +7, mice were bled, and
depletion of CD8+ T cells was confirmed in PBMCs by flow cytometry (A). After ZIKV challenge, mice were monitored for mortality (B) (log-rank test with Bonferroni
correction; CD8+ T cell-depleted mice were compared to the isotype-control mAb-treated mice in the same vaccine group: ns, not significant). Data are pooled
from two experiments (n = 20–35 animals per vaccine group).
(C, D, and F) Serum samples collected at day 45 from mice that received two doses of GAd-control, GAd-Eecto, or GAd-Zvp were passively transferred to 10- to
12-week-old wild-type mice (n = 10 per group) or congenic C1q/ (n = 9–17 animals per group) mice 1 day prior to challenge with 3 3 105 FFUs of ZIKV Dakar
41525 following anti-Ifnar1 mAb treatment. Wild-type mice were followed for mortality (C) and weight change (D), while C1q/ mice (F) were only followed for
mortality. Data are pooled from three experiments (survival analysis: log-rank test with Bonferroni correction: ***p < 0.001; ****p < 0.0001; weight change analysis:
two-way ANOVA with a Sidak’s post-test to compare vaccine groups relative to control group: ****p < 0.0001).
(E) Serum samples collected at day 45 from mice that received two doses of GAd-Eecto were evaluated by FRNT with or without addition of exogenous
complement protein C1q. EC50 values are shown and were analyzed for differences using a paired t test (****p < 0.0001).

ZIKV neutralizing antibody titers, and ELISA was conducted to
assess ZIKV E-specific binding antibody titers. ZIKV neutralizing antibody titers induced by GAd-Zvp single immunization
were elevated at 10 weeks post-immunization (EC50 of
1,206 ± 865), peaked at 18 weeks post-immunization (EC50
of 2,168 ± 1378), and then waned slightly at 38 weeks postimmunization (Figure 4A). A similar trend was observed with
ZIKV E-specific IgG (Figure 4B), with reciprocal mean
endpoint titers of 167,523 ± 110,941, 108,783 ± 50,306, and
52,923 ± 51,398 at 10, 18, and 38 weeks after a single immunization, respectively. In comparison, two immunizations
induced higher levels of neutralizing antibodies at 10 weeks
post-initial immunization (EC50 of 3,029 ± 1,604) that declined
at 18 (EC50 of 2,200 ± 1,757) and 38 weeks (EC50 of 402 ±
237) post-initial immunization (Figure 4C). ZIKV E-specific

IgG, however, remained more stable after two immunizations
(Figure 4D), with mean titers of 110,582 ± 55,508, 148,188 ±
60,419, and 106,644 ± 39,268 at 10, 18, and 38 weeks
post-initial immunization, respectively.
To assess the durability of protective efficacy of GAd-Zvp,
mice were immunized with the same regimens described
above and then challenged with a lethal dose of ZIKV Dakar
41525 at 10, 18, or 38 weeks post-initial immunization. One
day prior to ZIKV infection, mice were treated with a single
dose of anti-Ifnar1 mAb. All mice that received one or two immunizations of GAd-Zvp exhibited no weight loss and survived lethal ZIKV challenge at 10, 18, and 38 weeks, whereas
most of the GAd-control-vaccinated mice succumbed to ZIKV
infection with significant weight loss observed (Figures
4E–4P).
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Figure 4. GAd-Zvp Induces Durable Protective Immunity
C57BL/6 mice received one or two doses of GAd-Zvp or GAd-control.
(A–D) Humoral immune responses were evaluated in the sera of immunized mice at 10, 18, and 38 weeks post-initial immunization. An ELISA measured ZIKV
E-specific binding IgG (B and D), and a FRNT determined neutralization activity (EC50 values are shown; A and C). Humoral responses data are pooled from two
experiments with n = 6–12 per group.
(E–P) Mice that were immunized with one or two doses of GAd-Zvp or GAd-control were challenged with 3 3 105 FFUs of ZIKV Dakar 41525 following anti-Ifnar1
mAb treatment at 10, 18, and 38 weeks post-initial immunization (n = 10–12 mice per group) (survival analysis: log-rank test followed by Bonferroni correction:
**p < 0.01; ***p < 0.001; ****p < 0.0001; weight change analysis: two-way ANOVA with Sidak’s post-test correction: *p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001). Dotted lines represent the LOD of the assays, and bars indicate the median values.

GAd-Zvp Protects Pregnant Mice and Their Fetuses
against ZIKV Infection
As ZIKV causes congenital anomalies in fetuses from mothers infected during pregnancy, a key property of a ZIKV vaccine will be
its ability to protect against vertical transmission. We used both
immunocompromised and immunocompetent mouse models of
ZIKV challenge to assess the efficacy of GAd-Zvp during pregnancy (Figure 5A). In the immunocompromised mouse model,
4-week-old C57BL/6 female mice were immunized with either
GAd-Zvp or GAd-control vaccines by intramuscular inoculation.
A homologous booster vaccine dose was administered 21 days
later. At day 49 (4 weeks post-boost), immunized females were
mated with males and monitored for vaginal plugs. At embryo
day 5 (E5), pregnant females were administered a single 2 mg
dose of anti-Ifnar1, to facilitate virus dissemination to the
placenta (Richner et al., 2017b). At E6, the pregnant females
were challenged with 3 3 105 FFUs of ZIKV Dakar 41525. Mice
were euthanized at E13, and maternal and fetal organs were har-
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vested for viral burden analysis. In maternal, placental, and fetal
tissues from the majority of GAd-Zvp immunized dams, there
was little or no detectable viral RNA (Figures 5B–5E). However,
one GAd-Zvp-vaccinated dam showed breakthrough, with
ZIKV RNA present in the placenta and fetal heads, although
the levels were substantially reduced (20,800- and 12,800-fold
in the placenta and fetal head, respectively) compared to GAdcontrol-treated dams.
For the immunocompetent challenge model during pregnancy, hSTAT2-KI C57BL/6 mice were used (Gorman et al.,
2018); in this transgenic mouse, human STAT2 replaces mouse
Stat2, which allows ZIKV to overcome a species restriction barrier and evade IFN signaling cascades in infected cells (Grant
et al., 2016). Four-week-old hSTAT2-KI females were immunized
and boosted with GAd-Zvp or GAd-control vaccines by intramuscular inoculation according to the described scheme (Figure 5A). Twelve-week-old hSTAT2-KI females were mated with
hSTAT2-KI males and monitored for vaginal plugs. At E6

Figure 5. GAd-Zvp Protects Pregnant Mice and Their Fetuses against ZIKV Infection
(A) Representation of the immunization and infection scheme.
(B–E) Immunized 12- to 13-week-old wild-type C57BL/6 female mice were mated with wild-type C57BL/6 males. At E5, pregnant mice were given a single 2 mg
dose of anti-Ifnar1 mAb. At E6, pregnant mice were inoculated with 3 3 105 FFUs of ZIKV Dakar 41525 by a subcutaneous route. At day E13, mice were
euthanized and maternal spleen (B), maternal brain (C), placenta (D), and fetal heads (E) were harvested and assayed for ZIKV RNA levels.
(F–I) Immunized 11- to 12-week-old hSTAT2-KI C57BL/6 female mice were mated with hSTAT2-KI C57BL/6 males. At day E6, pregnant hSTAT2-KI mice were
challenged with 3 3 105 FFUs of ZIKV Dakar 41525 by a subcutaneous route. Mice were euthanized at day E13 and maternal spleen (F), maternal brain (G),
placenta (H), and fetal heads (I) were harvested and assayed for ZIKV RNA levels. Dotted lines indicate the LOD of the assays, and bars represent median values.
Data are from at least three experiments, with the following number of pregnant mice analyzed: wild-type + anti-Ifnar1 mAb treatment; GAd-control, n = 5; GAdZvp, n = 8; hSTAT2-KI mice; n = 6 for GAd-control or GAd-Zvp. The numbers of placenta and fetal heads analyzed are indicated in the figure. Statistical significance was determined by a Mann-Whitney test: **p < 0.01; ***p < 0.001; ****p < 0.0001.

(approximately 5 weeks post-boosting), pregnant hSTAT2-KI females were challenged with 3 3 105 FFUs of ZIKV Dakar 41525.
At E13, mice were euthanized, and maternal and fetal organs
were harvested. With the exception of a breakthrough in one
placenta and its associated fetus, the remainder of placental
and fetal tissues from GAd-Zvp immunized dams were negative
for viral RNA (Figures 5F–5I). In comparison, those vaccinated
with GAd-control vaccine showed significant levels of infection
in both fetal tissues.
DISCUSSION
The development of a ZIKV vaccine remains an urgent global
public health need due to its deleterious effects on unborn fetuses of infected mothers. In the few years since the epidemic
emerged, several vaccine candidates have been developed using multiple platforms including mRNA, inactivated virion, live-

attenuated or chimeric virus, purified E protein, VLPs, and viral
vectors-based ZIKV vaccines (Abbink et al., 2016; 2017;
Cox et al. 2018; Dowd et al., 2016b; Emanuel et al., 2018; Kim
€rnberger
et al., 2016; Li et al., 2018; Muthumani et al., 2016; Nu
et al., 2019; Pardi et al., 2017; Richner et al., 2017a, 2017b,
Shan et al., 2017a, 2017b; Xu et al., 2018). Three DNA vaccines
encoding ZIKV prM and E and one inactivated virus vaccine have
completed evaluation in phase I trials in humans (Gaudinski et al.,
2018; Modjarrad et al., 2018; Tebas et al., 2017). Although many
of these vaccines have shown efficacy in pre-clinical challenge
models, fewer studies have been performed in the context of vertical transmission, and none have used an immunocompetent
mouse model with robust replication after peripheral inoculation
(Gorman et al., 2018).
A GAd that was recently isolated has been developed as a
vaccine vector for pathogens to overcome the pre-existing
Ad5 immunity in humans (Brough, 2015; Duncan et al., 2013;
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Johnson et al., 2014). We utilized this vector to develop vaccines
expressing a soluble form of ZIKV E protein (GAd-Ecto) or the
full-length prM-E proteins (GAd-Zvp), which assemble into
VLPs (Garg et al., 2017; Yang et al., 2017). Both of our vaccine
candidates induced neutralizing antibodies, although the titers
achieved with GAd-Eecto were substantially less than GAdZvp. Epitope localization analysis revealed that GAd-Zvp preferentially induced antibodies that bound a key neutralizing epitope
on the LR of DIII of E protein (Nybakken et al., 2005; Oliphant
et al., 2005; Robbiani et al., 2017; Wang et al., 2017; Zhao
et al., 2016), whereas GAd-Eecto did not. The basis for this difference in immunogenicity remains uncertain but could reflect
the display of antigens on the multivalent VLP generated by
expression of prM-E compared to the soluble E protein. Notwithstanding this idea, a measles-based ZIKV vaccine expressing
soluble E protein appeared to generate high levels of neutralizing
antibodies, although no comparisons with prM-E were attemp€ rnberger et al., 2019). One question that reted in that study (Nu
mains is whether neutralizing antibody responses to GAd-Zvp in
humans would similarly target the DIII-LR epitope since for some
flaviviruses (e.g., West Nile virus [WNV] and Dengue virus
[DENV]) this epitope is more immunodominant in mice than in humans (Beltramello et al., 2010; Oliphant et al., 2007). Although
epitope-based analysis of human antibody responses to the
GAd-Zvp ultimately will be required to address this question,
several highly protective human DIII-LR antibodies have been
isolated against natural ZIKV infection (Robbiani et al., 2017;
Sapparapu et al., 2016; Wang et al., 2017, 2016). These results
suggest that humans can make protective DIII-LR-specific antibodies in response to ZIKV structural protein antigens. Despite
the differences in humoral response, both GAd-Eecto and
GAd-Zvp vaccines protected against lethal ZIKV challenge in
mice. A single GAd-Zvp immunization resulted in durable protection in mice even nine months later, with only a slight decline in
neutralizing antibody titers. Finally, GAd-Zvp demonstrated
marked protection against maternal-to-fetal transmission of
ZIKV in two different mouse models, with the vast majority of fetuses showing no evidence of infection.
Several human and nonhuman adenovirus-based ZIKV vaccines have been evaluated. A single dose of RhAd52 expressing
ZIKV M-E induced durable neutralizing immunity that conferred
protection against challenge 1 year post-vaccination in rhesus
monkeys. Moreover, passive transfer of purified IgG from rhesus
monkeys at 1 year post-vaccination to mice resulted in protection against ZIKV challenge (Abbink et al., 2017). Similarly,
Ad26 expressing the same ZIKV M-E transgene induced humoral
and cellular immune responses and protected mice and NHPs
against viremia upon ZIKV challenge (Cox et al., 2018). A hAd5
vaccine candidate expressing codon-optimized ZIKV M-E in
which the transmembrane domain was replaced by a T4 fibritin
foldon trimerization domain induced neutralizing antibodies in
mice (Kim et al., 2016). This vaccine also protected pups of
immunized dams that were infected with ZIKV at day 7 postbirth. A chimpanzee adenovirus (ChAd7) expressing ZIKV M
and E proteins elicited neutralizing antibodies, T cell responses,
and conferred protection against lethal virus challenge (Xu et al.,
2018). A direct comparison of many of the published ZIKV vaccination platforms including their dosing, neutralizing activity, and
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protection conferred in mice is summarized (Table S1). While the
majority of studies with these vectored and other subunit, inactivated, or live-attenuated vaccine platforms evaluated serum
antibody titers after immunization, none interrogated long-term
MBC responses. Moreover, only a few other ZIKV vaccines
have established protection against congenital transmission
€rnberger et al., 2019; Richner et al.,
during pregnancy (Nu
2017b; Shan et al., 2017b).
The GAd-Zvp vaccine effectively minimized vertical transmission during pregnancy in the immunocompromised challenge
model. There was little, if any detectable viral RNA in the
placental and fetal tissues with the exception of breakthrough
in one of the dams, and, even then, the levels of infection were
much lower than in GAd-control-treated dams. Similar levels of
GAd-Zvp-mediated protection were seen in the immunized
immunocompetent hSTAT2-KI mice. The clinical significance
of the low levels of viral RNA in the placenta and fetus that
occurred in the context of vaccine breakthrough remains unknown. Moreover, these events occurred in the setting of detectable neutralizing antibody, as seen previously with modified
mRNA or live-attenuated ZIKV vaccines (Richner et al., 2017b;
Shan et al., 2017b). The mechanistic basis for this breakthrough
in the setting of neutralizing antibody warrants further studies but
could reflect virus that is transmitted by cells in blood rather than
in plasma (Michlmayr et al., 2017).
Many animal experiments have established that vaccineinduced or passively transferred neutralizing antibodies represent
a correlate of protection against flavivirus infection (BelmustoWorn et al., 2005; Ben-Nathan et al., 2003; Diamond et al., 2003;
Engle and Diamond, 2003; Heinz et al., 2007; Mason et al., 1973;
Swanstrom et al., 2016). Indeed, several studies with ZIKV vaccines have suggested that neutralizing antibodies are a likely
correlate of protection (Abbink et al., 2016; Dowd et al., 2016b; Larocca et al., 2016; Richner et al., 2017a; Sapparapu et al., 2016).
Passive transfer of serum from GAd-Eecto and GAd-Zvp immunized mice was sufficient to confer protection against lethal ZIKV
challenge in mice. However, when passive transfer experiments
were repeated in C1q/ mice, serum from GAd-Zvp- but not
GAd-Eecto-immunized mice conferred protection. This finding
suggests that the protection provided by the GAd-Ecto-induced
antibodies, which are less neutralizing, is complement dependent
and is consistent with the concept that C1q binding to the Fc region
of antibody reduces the stoichiometric threshold of neutralization
and improves antibody protection against flaviviruses (Mehlhop
et al., 2009). The lower neutralizing antibody response observed
with GAd-Eecto may be due to the different presentation of E protein epitopes. Whereas GAd-Zvp, which encodes for full-length
prM and E, produces VLPs, GAd-Eecto produces a soluble form
of E protein. VLPs are multivalent, repetitive antigen structures
that morphologically resemble infectious virions but lack viral
RNA and capsid (Allison et al., 1995; Rodrı́guez-Limas et al.,
2013). The more potent antibody responses associated with particulate VLPs also could be explained by (1) the ability of particles
of this size to traffic to lymph nodes, bind to follicular dendritic cells,
and induce primary antibody responses (Reddy et al., 2006); (2)
efficient binding of VLPs to IgM and complement with subsequent
presentation of VLPs antigens to B cells in the lymph nodes (Link
et al., 2012); and (3) VLPs induce potent T helper responses as a

result of efficient uptake and processing by antigen-presenting
cells (Bachmann and Jennings, 2010). Although antigen-specific
CD8+ T cell responses also were generated upon immunization
and have been shown protective during primary ZIKV infection
(Elong Ngono et al., 2017; Huang et al., 2017; Winkler et al.,
2017), depletion studies suggest they had a subordinate role in
GAd vaccine-mediated immunity.
A single dose of GAd-Zvp induced a durable immune
response that protected mice against lethal ZIKV challenge
9 months later. The durable IgG response likely is produced by
LLPCs, which reside in the bone marrow and continuously
secrete antibodies into circulation independently of antigen
exposure (Amanna and Slifka, 2010). Although GAd-Zvp induced
a robust LLPC response, GAd-Eecto did not appear to. This
could be attributed to the nature of the antigen produced in
each vaccine. The repetitive arrangement of envelope proteins
on the surface of VLPs produced by GAd-Zvp likely facilitates
enhanced recognition by B cells (Metz and Pijlman, 2016) and
transmission of a potent activation signal (Jegerlehner et al.,
2002) that could influence differentiation of LLPCs.
In summary, we have shown that immunization with GAd-Zvp
resulted in robust and durable neutralizing antibody responses
as well as cellular immune responses including antigen-specific
CD8+ T cells, MBCs, and LLPCs. A single immunization of GAdZvp was sufficient to confer durable protection against lethal
ZIKV challenge and two doses conferred protection against vertical transmission of ZIKV in pregnant mice in two different
models. Given the safety profiles of recombinant adenovirus
vectors established in hundreds of clinical trials, the scalable
manufacturing of millions of doses using approved cell lines,
the low seroprevalence of GAd that overcomes pre-existing
hAd5 immunity, and finally the efficacy of preclinical evaluation
shown in this study, GAd-Zvp is a promising vaccine candidate
that warrants further evaluation.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Viruses and cells
ZIKV strain Dakar 41525 (Senegal, 1984, GenBank: KU955591) was provided by the World Reference center for Emerging Viruses
and Arboviruses (R. Tesh and S. Weaver, University of Texas Medical Branch) and adapted by passage in Rag1/ mice (Gorman
et al., 2018). In some experiments, ZIKV strain H/PF/2013 (French Polynesia, 2013) was used (obtained from X. de Lamballerie,
Aix Marseille Université). Virus stocks were propagated in Vero cells and titrated by focus-forming assay (FFA), as previously
described (Lazear et al., 2016).
Mouse experiments
Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington
University School of Medicine (Assurance number A3381-01). Virus inoculations were performed under anesthesia that was induced
and maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.
C57BL/6 mice were purchased from The Jackson Laboratory (catalog 000664), and congenic hSTAT2-KI (Gorman et al., 2018) and
C1q/ mice (Botto et al., 1998) were bred in pathogen-free animal facilities at Washington University School of Medicine. Immunizations were conducted by inoculating vaccines in 50 ml via intramuscular route. ZIKV challenges were performed by subcutaneous
inoculation in the footpad with 3 3 105 FFU of mouse-adapted ZIKV Dakar 41525 in 30 ml of PBS. In some mice, ZIKV infections were
preceded by administration of 2 mg of anti-Ifnar1 blocking antibody (MAR1-5A3, Leinco (I-1188)) via intraperitoneal injection. For
pregnancy experiments, wild-type C57BL/6 or hSTAT2-KI female were mated with naive wild-type male mice or hSTAT2-KI males,
respectively; at E5, pregnant dams (wild-type C57BL/6 mice only) were treated with a 2-mg injection of anti-Ifnar1 antibody. At E6,
mice were inoculated with 105 FFU of mouse-adapted ZIKV Dakar 41525 by subcutaneous injection in the footpad. Animals were
sacrificed at E13, and placentas, fetuses, and maternal tissues were harvested.
METHOD DETAILS
Construction and generation of GAd vectors
The genomes of GAd-Zvp and GAd-Eecto vectors were generated by homologous recombination using the plasmid
pACgc46E1(d2t.L) containing the E1-deleted genome of GAd clone GC46 and the derivatives of shuttle plasmid
pGC46CMVTetO.MCS.SV (plasmids provided by Precigen). Plasmids were transformed into E. coli strain BJ5183 as previously
described (Duncan et al., 2013). The cDNA insert of GAd-Zvp was comprised of the IL-2 signal sequence, the coding region on
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prM gene, the full-length E gene of ZIKV H/PF/2013 polyprotein (nucleotides 414-2429, Accession #; Baronti et al., 2014 KJ776791.2)
and a stop codon (TGA); this construct was cloned into the shuttle plasmid pGC46CMVTetO.MCS.SV under transcriptional control of
CMV promoter followed by an SV40 polyadenylation signal in place of E1 genes deleted in GAd genome. The cDNA insert of GAdEecto was comprised of the IL-2 signal sequence, the coding region on prM gene, the E gene lacking its transmembrane domain
(nucleotides 414-2135 of ZIKV H/PF/2013) followed by a hexa-histidine tag and stop codon. The pGAd-Zvp and pGAd-Eecto plasmids were linearized with PmeI and transfected into M2A cells to rescue and upscale replication-incompetent GAd-Zvp or GAdEecto vectors (Gall et al., 2007). The E1-deleted vector GC46Null, which does not express any transgenes, was provided by Precigen
and used as a negative control (GAd-control). Recombinant viruses were purified using cesium chloride density-gradient ultracentrifugation, and the number of virus particles (vp) was determined using optical density (260 nm) measurement as previously
described (Mittereder et al., 1996). To confirm expression of the constructed ZIKV prM-Eecto and prM-E transgenes, A549 cells
were mock-infected or infected with GAd-Zvp or GAd-Eecto vector at multiplicity of infection (MOI) of 1,000 virus particles/cell,
and the presence of E protein in the supernatants of infected cells was examined 5 days post-infection by western blotting using
an anti-ZIKV mAb (ZV-48; Zhao et al., 2016).
Negative staining and transmission electron microscopy
A549 cells were inoculated with GAd-Zvp or GAd-Eecto at a MOI of 1,000. The supernatants were harvested five days later, clarified
by centrifugation at 4,000 rpm for 10 min at 4 C, loaded over a 20% w/v sucrose cushion in TNE buffer (10 mM Tris-HCl, pH 8.0,
120 mM NaCl and 1 mM EDTA), and pelleted by ultracentrifugation at 32,000 rpm at 4 C for 2 h. Purified VLPs were collected
and imaged by electron microscopy. Samples were absorbed onto freshly glow discharged formvar/carbon-coated copper grids
for 10 min. Grids were washed in dH2O and stained with 1% aqueous uranyl acetate (Ted Pella Inc.) for 1 min. Excess liquid was
wicked off gently, and grids were air-dried. Samples were viewed on a JEOL 1200EX transmission electron microscope
(JEOL USA) equipped with an AMT 8 megapixel digital camera (Advanced Microscopy Techniques). The nominal magnifications
used were 50,000, and 10,000. A ZIKV VLP preparation generated from 293T cells was used as a positive control.
ELISA
The ZIKV E-binding IgG responses were determined using an ELISA, as previously described (Zhao et al., 2016). Briefly, Maxisorp
96-well plates (Nunc) were coated with recombinant ZIKV E protein (Meridian Life Science Inc.) overnight at 4 C. On the next day,
plates were washed extensively with PBS with 0.02% Tween 20 (PBS-T) and then blocked with 5% BSA in PBS-T for 1 h at
37 C. Serially diluted serum samples were added to the wells and incubated for 1 h at room temperature followed by washing
and 1 h incubation with biotin-labeled goat anti-mouse IgG (Sigma) at room temperature. After additional washing, ZIKV E-binding
IgG were detected using an HRP-conjugated streptavidin (1 h at room temperature) and tetramethylbenzidine substrate. The reaction
was then stopped by addition of 1 N sulfuric acid and optical density (450 nm) measurements were determined using microplate
reader (Bio-Rad). A similar ELISA was prepared with plates coated with recombinant ZIKV Eecto, DIII or DIII-LR mutant (A310E
and T335K) (Zhao et al., 2016) to assess polyclonal antibody reactivity to the DIII-LR epitope. A simliar ELISA was conducted to determine serum anti-NS1 titers, with recombinant ZIKV NS1 (Native Antigen) used as the solid phase antigen.
Neutralization assay
A FRNT measured ZIKV neutralizing antibody, as previously described (Zhao et al., 2016). Briefly, heat-inactivated sera were serially
diluted and incubated with 102 FFU of ZIKV (strain H/PF/2013) for 1 h at 37 C. The ZIKV-serum mixtures were added to Vero cell
monolayers in 96-well plates and incubated for 1 h at 37 C followed by overlaying the cells with 1% (w/v) methylcellulose in
MEM. Cells were incubated for 40 h and subsequently fixed using 1% PFA in PBS for 1 h at room temperature. ZIKV-infected cell
foci were detected using anti-WNV E60 [(500 ng/ml), (Oliphant et al., 2006)] followed by horseradish-peroxidase-conjugated goat
anti-mouse IgG (Sigma) in PBS supplemented with 0.1% (w/v) saponin (Sigma) and 0.1% BSA. TrueBlue peroxidase substrate
(KPL) was used to develop the plates before counting the foci on a BioSpot analyzer (Cellular Technology Limited).
MBC limiting dilution assay
MBC responses were determined by measuring the levels of ZIKV E-specific IgG in the supernatants of CD19+ B cells cocultured with
NIH 3T3 feeder cells ectopically expressing CD40L, IL-21, and BAFF following protocols adapted from published papers (Amanna
and Slifka, 2006). Single cell suspensions were prepared from spleens of immunized mice. Erythrocytes were lysed with ACK lysis
buffer, and CD19+ B cells were isolated by positive selection using magnetic beads (Miltenyi Biotec). Feeder cells were treated with
5 mg/mL of mitomycin (Sigma) to prevent proliferation, and CD19+ B cells were cocultured in RPMI supplemented with 10% FBS,
penicillin and streptomycin, 10 mM HEPES pH 7.3, 50 mM b-mercaptoethanol, and 10 mM nonessential amino acids, in a twofold
serial dilution starting at 106 cells/well in a 96-well plate. Plates were incubated at 37 C in a CO2 incubator for 6 days. The frequencies
of ZIKV E-specific MBC were determined using an ELISA for ZIKV E-specific IgG as described above and Poisson distribution analysis. Positive wells were defined as wells that scored twofold over the mean optical density of negative control wells (wells containing
irradiated splenocytes and supplements alone). Supernatant from cultured naive splenocytes did not score positive, and only limiting
dilution assays that contained at least two positive wells at the highest dilution were analyzed.
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ELISPOT assay
An ELISPOT assay quantitated the number of ZIKV E-specific LLPCs in the bone marrow, as previously described (Purtha et al.,
2011). ELISPOT plates (Millipore) were coated with ZIKV E protein overnight at 4 C. Subsequently, plates were washed twice with
PBS-T, then twice with PBS and then blocked for 1-3 h with RPMI supplemented with 10% FBS, penicillin and streptomycin,
10 mM HEPES pH 7.3, 50 mM b-mercaptoethanol, and 10 mM nonessential amino acids (RPMI-Complete). Bone marrow cells
were harvested from the femurs of immunized mice, and erythrocytes were lysed by ACK lysis buffer. Subsequently, CD138+ plasma
cells were enriched by positive selection using magnetic beads (Miltenyi Biotec), resuspended in RPMI-Complete at 107 cells/ml,
serially diluted in the coated ELISPOT plates, and incubated overnight at 37 C in a CO2 incubator. Plates then were washed five times
with PBS, incubated with 1% NP40 in PBS for 20 min at room temperature, and washed three times with PBS-T. Plates were incubated with biotinylated anti-mouse IgG (Sigma) in PBS-T with 1% FBS for 1 h at room temperature. Following washing with PBS-T,
plates were incubated with HRP-conjugated streptavidin (1 h at room temperature). Spots were developed with trueBlue peroxidase
substrate (KPL) before the reaction was quenched with water and counted with a BioSpot analyzer (Cellular Technology Limited).
Measurement of viral burden
ZIKV-infected mice were euthanized using a ketamine/xylazine cocktail on the indicated days post-infection, and blood and organs
were collected. Serum was separated from coagulated blood, and tissues were weighed and homogenized with beads using a
MAgNA Lyser (Roche). RNA was extracted using RNeasy Mini Kit or RNeasy 96 kit (QIAGEN). Viral RNA levels were measured using
TaqMan one-step quantitative reverse transcriptase PCR (RT-qPCR) on an ABI 7500, after comparison with a standard curve generated using 10-fold serial dilution of viral RNA from known infectious virus quantities. Viral burdens were expressed as viral RNA equivalents per gram or milliliter on a log10 scale. For RT-qPCR, published ZIKV primers and probe set were used (Richner et al., 2017a):
Forward 50 -CCACCAATGTTCTCTTGCAGACATATTG-30 ; Reverse 50 - TTCGGACAGCCGTTGTCCAACACAAG-30 ; Probe 50 -/56 FAM/
AGCCTACCT/ZEN/TGACAAGCAGTC/3IABkFQ/-30 (Integrated DNA Technologies).
Intracellular Cytokine Staining
Freshly-isolated mouse splenocytes were stimulated with an H-2Db-restricted immunodominant ZIKV peptide (amino acids 294302), with rat anti-mouse CD3 used as a positive control and medium as negative control, for 12 h at 37 C before brefeldin A
(BioLegend, 420601) was added for an additional 4 h. Subsequently, single-cell suspensions were blocked for FcgR binding
(BioLegend; clone 93) and stained with the following antibodies: CD45 BUV395 (BD BioSciences clone30-F11), CD62L Pacific
Blue, KLRG1 FITC, CD44 PE, CD4 PE-Cy7, CD8b PreCP-Cy5.5, CD19 APC-Cy7 (BioLegend clones MEL-14, 2F1/KLRG1, IM7,
GK1.5, YTS156.7.7, 6D5, respectively), CD127 Alexa700 (eBioScience clone A7R34), and fixable viability dye (eFluor 506,
eBioscience). Subsequently, cells were fixed and permeabilized with Foxp3/Transcription Factor Staining Buffer Set (eBiosciences,
00-5523-00) followed by intracellular staining with anti-TNF-a BV605 and anti-IFN-g Alexa 647 (BD Biosceinces clones MP6-XT22
and XMG1.2, respectively). Datasets were acquired on a LSRII flow cytometer and analyzed using FlowJo software X 10.0.7.
CD8+ T cell depletion
To deplete CD8+ T cells, anti-CD8a (BioXCell; clone YTS169.4; 500 mg) or an isotype control (BioXCell; clone LTF-2; 500 mg)
was administered to immunized mice by intraperitoneal injection at days 7, 3, +1, +5 and +12. Mice then were challenged with
3 3 105 FFU of mouse-adapted ZIKV Dakar (41525) at day 0 that was preceded by intraperitoneal inoculation of anti-ifnar1 blocking mAb. To confirm immune cell depletion, peripheral blood was collected at 7 dpi followed by erythrocyte lysis with ACK lysis buffer
(GIBCO) and resuspension in RPMI supplemented with 10% heat-inactivated FBS. Cells were blocked for FcgR binding and stained
with CD45 BUV395 (BD BioSciences clone30-F11), CD3 Alexa488 (BioLegend clone1452C11), CD4 PE-Cy7 (BioLegend clone
GK1.5), CD8b PreCP-Cy5.5 (BioLegend clone YTS156.7.7), and Fixable Aqua Dead Cell Stain (Invitrogen, L34966). Subsequently,
cells were fixed by Fix/Lyse solution (eBioSciences 00-5333). Datasets were acquired on a LSRII flow cytometer and analyzed using
FlowJo software X 10.0.7.
QUANTIFICATION AND STATISTICAL ANALYSIS
Specific statistical tests used to analyze experimental datasets are described in the respective Figure Legends. For antibody responses and immune cell analyses, one-way ANOVA with Dunn’s or Dunnett’s post-test was used. For viral titer data analysis, a
Mann–Whitney test or a Kruskal–Wallis ANOVA with Dunn’s post-test correction was used. Survival curves were analyzed using
the log rank test with a Bonferroni correction, and weight change was evaluated with a two-way ANOVA with a Dunnett’s posttest or with two-way ANOVA with Sidak’s post-test correction. A P value of < 0.05 was assigned to establish statistical significance
using GraphPad Prism version 7.0.
DATA AND CODE AVAILABILITY
The published article includes all data generated or analyzed during this study. Original source data for Figures in the paper are
available upon request to the Lead Contact author. No proprietary software was used in the data analysis.
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Table S1. Evaluation of ZIKV vaccine platforms in mice, Related to all Figures

Vaccine platform
#
Doses

Vaccine Efficacy in mice
Neutralization
Protection against
titer
ZIKV challenge

Reference
Protection against
in utero
transmission
Yes

This study

Gorilla adenovirus encoding
prM-E (GAd-Zvp)

1 or 2

FRNT EC50
1,796 ± 919

Yes
(No viremia or
lethality)

Ad26.ZIKV.M-Env

1

FRNT EC50
~ 1,000

Yes
(No viremia)

N.D.*

(Cox et al., 2018)

Chimpanzee adenovirus type 7
(AdC7-M/E)

1

MN50
~1,000

Yes
(No viremia or
lethality)

N.D.

(Xu et al., 2018)

mRNA encoding prM-E

2

FRNT EC50
10,000

Yes
(No lethality)

Yes

(Richner et al., 2017a, 2017b)

DNA encoding prM-E

1

MN50
22

Yes
(No viremia)

N.D.

(Larocca et al., 2016)

DNA encoding E

1

NN50
<10

No
(viremia detected)

N.D.

(Larocca et al., 2016)

Measles-vectored prM-Zika-sE

2

PRNT50
40 - 1,280

Yes
(Viremia and organ
viral loads reduced)

Yes **

(Nürnberger et al., 2018)

ZIKV-3′UTR-Δ10-LAV
(live attenuated)

1

FRNT EC50
18,900 ± 5,900

Yes
(No lethality)

Yes

(Shan et al., 2017a, 2017b)

DNA encoding prM-E

1

PRNT50
456 ± 5

Yes
(No lethality)

N.D.

(Muthumani et al., 2016)

DNA encoding prM-E

1

Purified inactivated virus

1

hAd2-vecored
prM-E, prM-E-NS1

2

RVP
~1000-100000
MN50
15
MN50
~1,000

ND

N.D.

(Dowd et al., 2016)

Yes
(No viremia)

N.D.

(Larocca et al., 2016)

Yes***

N.D.

(Liu et al., 2018)

*N.D. = not determined; FRNT, focus reduction neutralization test; PRNT, plaque reduction neutralization test; MN, microneutralization test; RVP, reporter
virus particles.
** Reduced viremia and viral loads in fetuses and maternal tissues
*** Challenge in pups born to immunized dams showed reduced viral loads in brain and testis

